"Name calling ... simply is of no moment to me. I embrace it," says Erich Spangenberg of Celgene IPR motion. http://t.co/BDzcL7Z45T
US consumers subsidise wealthy Europeans. https://t.co/wGZhryaaCn
IAM exclusive: Spangenberg responds to Celgene IPR motion $CELG http://t.co/BDzcL7Z45T
Yesterday the pharmaceutical company Celgene filed a motion for sanctions against Kyle Bass and Erich Spangenberg and their Coalition for Affordable Drugs, accusing them of abusing the inter partes review (IPR) process. In what has quickly become the patent story of the year Bass and Spangenberg have filed a series of IPRs against what they see as weak pharmaceutical patents that should never...
Brazil joins India as a jurisdiction in which patent-light Chinese smartphone makers may fear to tread
It increasingly looks like we are on the cusp of entering a second round of smartphone patent wars, driven by the expansion of China’s fast-moving, lower-end mobile device manufacturers outside of their home markets. Earlier this month, Brazil’s competition regulator – the Conselho Administrativo de Defesa Economica (CADE) – handed down a decision that underlines just...
The multi-year, worldwide and ongoing litigation battle between ZTE and non-practising entity (NPE) Vringo took an interesting twist last week when a series of internal ZTE documents were filed with a New York court. The documents, which largely consist of communications between ZTE staff, detail how the Chinese telecom company has set out to wage a “PR battle” against Vringo as...
IAM Patent 1000
The definitive guide to leading patent lawyers, attorneys and firms in over 40 jurisdictions, with a special section on expert witnesses in the United States.Visit site